Member Info for AquaeSulis01

oops, but guess I could always argue that Roger was "Airing" his views on the BB

roger, always correct to air on the side of caution with risky stocks but as a considered investment this is as good as any in the current climate with the short term timing of potential game-changing results. What I would say about PJ, is that he has continued to add to his substantial skin-in-the-game at full market rates despite having had the opportunity to take up options at a discount, and that is a very rare AIM CEO indeed. At the end of the day, all any of us can do is trust our instincts and hope PJ becomes seriously wealthy on the back of this company taking us all along with him. He has certainly worked his socks off trying irrespective of the outcome of the drilling here

skid, wouldn't that imply that the Probiotix Health associate value should not be used to offset losses from the change in value of an investment?

Any accountants out there able to explain why Opti are able to report the value of an "Associate" in the Profit and Loss column in the same way that an "Investment" like Skinbiotherapeutics is reported? I expected the accounting LOSS of the Probiotic Heath Associate to be reported in the same way skinbiotherapeutics was prior to Optibiotic Health's holding reducing to a point where it could be reclassified as an investment? From the May 2020 EOY accounts "The share of loss from OptiBiotix's associate, SkinBiotherapeutics plc (SBTX), was £296,344. This is an accounting adjustment and has no impact on the Group's cash."
"The listing of ProBiotix on AQSE has created a previously unrecognised asset allowing the Company to report a circa £13.9m profit largely from the gain on this investment offset by a loss on revaluation of the SkinBioTherapeutics plc shares."

My porridge arrived today from H&B but unlike in the Bath store which had new stock, the online supply had a best before date of Jan 2023 so they still haven't sold their last year order of slimbiome products. :(

Clio one small point, Stuart didn't say signing many small deals would be more difficult than signing fewer multi national deals, he said it would be difficult to unpick then once signed in order to move to bigger dea!s after

Friedman, it sounds as if we are paying to incorporate the xylooligosaccharide into our OptiXOS product and distributing that. This runs contrary to the original DSM agreement which envisaged royalties flowing in Opti's direction.

Certainly a curious RNS. The original RNS in Apr 2016 referenced referred to royalty payments "The agreement allows for collaboration between both parties to develop new products using OptiBiotix's OptiBiotic® technology platform.
If successful, the agreement allows both parties to agree commercial terms such that OptiBiotix grants an exclusive licence to DSM in the DSM field, and an option to license in other fields, in return for royalty payments on sales of future products."

I think SOH needs to provide a little more clarity around the current deal

Curious RNS out today from Opti. What caught my eye was the following reference "XOS also has a complementary effect on the growth and propagation of probiotics such as Lactobacillus plantarum and Lactobacillus rhamanosus (such as LGG). This creates the potential for probiotic companies to boost the health benefits of their existing products and create real differentiation in the market. This application has been researched by OptiBiotix as part of a joint development with DSM (announced 5 April 2016) and is covered by an extensive patent portfolio"
Lactobacillus rhamanosus is what our skinbiotix lysate is based on so may complement the use of our products going forward

Yes, certainly all about timing Clio . The VIP launch is likely to be highly significant once it happens. Despite the many products on the market, there remain only 3 scientifically proven anti ageing products available and that is shortly to become four; a momentous event.
https://estiloaomeuredor.com/en/these-are-the-only-3-scientifically-proven-anti-aging-products/

Clio, could you support a fund raise to launch the start of the acne consumer programme scheduled to commence in 2022?

Bit of additional analysis and derived estimates resulting from it which I hope will be helpful to fellow LTH's. I personally was completely wrong footed by the £75,000 end Jun Axis revenue figure, not because of the Elrico algo but because of the March half year RNS which stated that subscriptions had gone up by 335% Feb/Mar from the launch figures. I immediately thought that meant the £11,000 per month achieved Nov/Dec 2021 would treble, but of course I missed the subtle reference to subscription rather than revenue and hence total customers = subscription purchasers + non-subscription purchases and all that appears to have happened is that a number of non-subscriber Customers at launch became regular subscribers with no net increase in overall Customer numbers. Did anyone else fall into this trap?
Playing around with the £22,000 Nov/Dec Revenue figure, the 335% subscriber increase info and the Jun 2022 £75,000 revenue figure and factoring the 85% retention of SUBSCRIBERS, I estimate we started off with circa 80 subscribers (mainly made up of Bright Study participants) and as at end Jun 2022 have circa 270 subscribers and 100 non-subscribers.

Soz hit the post too early. Should include "This week, the Government will also scrap a plan to stop supermarkets from selling unhealthy foods at checkouts and ministers are preparing to end a sugar tax on soft drinks." https://www.telegraph.co.uk/politics/2022/09/24/liz-truss-plans-cut-taxes-new-year/

Talk about panic measures, and to help with the cost of obesity to the NHS

Toyin, thanks for the response but we'll agree to disagree on whether this was an Operational error. My line is that Stuart should not have spent hundreds of thousands of pounds on inventory before he had a firm strategy to shift it in place and the fact he changed his mind post the purchase confirms he did not have that strategy finalised. Stuart is the CEO and as such heads up the strategic direction the company takes and is responsible for getting it right. A strategy involves long term planning and it should not be necessary to change it a few months after having set it.
For such a small company, there appear to be as many chiefs as there are indians; a few more indians carrying out the "operational" level of the Business might mean we actually improve the marketing and sell a few more boxes of this world class product.

Toyin, Stuart did make one costly operational mistake, he bought enough inventory of axisbiotix, a shelf lifed product, to satisfy several thousand subscribers before he had finalised his strategy and now is incurring costs to store it and ship it back to Blighty. Last comment on the disappointing axis sales figures brought about the strategic change in direction, do we still need a Non-Exec Director brought in for her D2C skillset if we have no intent to pursue that avenue?
The Oral Healthcare results appear to have slipped under the radar on this BB. The original launch RNS April 2021 spoke of "The oral health programme will explore the use of different bacteria, including SkinBioTherapeutics' proprietary lysate, SkinBiotix®, for oral health and well-being. The programme will be led by Professor Andrew McBain and Dr Ruth Ledder from the School of Health Sciences at the University of Manchester." and "Stuart Ashman, CEO of SkinBioTherapeutics, said:

"This new oral health programme builds and expands on our work in skin health and applies our already substantial skin microbiome expertise to the global oral care marketplace. This new strand to our development portfolio also presents near term opportunities." Whilst the latest trading update stated "This study identified several bacteria/lysates each with differing abilities to protect oral cells. Future studies will identify the optimal bacteria/lysates to take forward into human studies.

The success of this first phase study provides a solid foundation for transition into future clinical studies and strongly positions SkinBioTherapeutics as a potential player in the periodontal disease treatment market, unlocking additional opportunities with global multinationals.". I don't see any near term opportunities i.e. using the skinbiotix lysate as is, here?
Finally, being a realist, whilst Stuart has said there will be no need to do a fundraise to keep the lights on, that doesn't rule out another fund raise to carry out further R&D. After all cash burn between Dec 2021 and Jun 2022 was £1.4M and that did not include Oral Healthcare R&D and Inventory costs which were paid for prior to end Dec 2021, and we had £1.8M left at end Jun 2022. I suspect that is the reason the share price is currently hovering where it is whilst holders wait to see the magnitude of any upfront Croda royalties

For info, sli m expert porridge with slimbiome now available half price at £5 per 10 sachet box online with H&B. Very nice mixed with sultanas.

Proactive interview. https://www.proactiveinvestors.ca/companies/news/993406/ceres-power-close-to-a-conclusion-on-milestone-china-agreements-993406.html#:~:text=Ceres%20Power%20close%20to%20a%20conclusion%20on%20milestone,China%20when%20he%20spoke%20with%20Proactive%27s%20Chris%20Rhodes.

Thanks Sandon, fairly superficial analysis then

Well that underwent down well with the markets

Anyone with a subscription want to enlighten us with Tempus logic?

The Times (Tempus share tips): BUY JD Sports; AVOID Ceres Power.